共 181 条
[1]
Berthold DR(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 242-245
[2]
Pond GR(2012)Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 983-992
[3]
Soban F(2013)Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 138-148
[4]
de Wit R(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[5]
Eisenberger M(2010)Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J Med Chem 53 2779-2796
[6]
Tannock IF(2009)Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science (New York, NY) 324 787-790
[7]
Fizazi K(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-1197
[8]
Scher HI(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216
[9]
Molina A(2013)Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 24 1807-1812
[10]
Logothetis CJ(2013)Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 1802-1807